# Abbott Laboratories operating income entity: /record/abbott-laboratories.md predicate: operating_income page: /record/abbott-laboratories/operating_income as_of: 2026-11-09 cite: AsOf. "Abbott Laboratories quarterly operating income: 1,358,000,000 United States dollar", as of 2026-09-30. Claim clm_2416CD508AED, https://asof.is/claim/clm_2416CD508AED, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm. As of November 9, 2026, the latest operating income figure on the AsOf record for Abbott Laboratories is $1.36 billion for the quarter ended September 30, 2026, from a primary source (sec.gov). Abbott Laboratories's latest full-year operating income is $8.05 billion, dated December 31, 2025, from a primary source (sec.gov); the two periods are kept apart, never compared. 19 claims on Abbott Laboratories's operating income, 1 open and 18 superseded, each dated and sourced; a replaced value is closed with an end date, never deleted. ## Latest operating income The newest figure for a shorter period, the quarter ended September 30, 2026: a quarterly_operating_income claim, kept apart from the full-year series. - [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_operating_income | 1,358,000,000 United States dollar | valid 2026-09-30 to present | conf 0.95 | valid | [clm_2416CD508AED](/claim/clm_2416CD508AED.md) sources: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm ## Latest full-year operating income What the record asserts on 2026-11-09. - [Abbott Laboratories](/record/abbott-laboratories.md) | operating_income | 8,053,000,000 United States dollar | valid 2025-12-31 to present | conf 0.95 | valid | [clm_551396362E4C](/claim/clm_551396362E4C.md) sources: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm ## Every dated value One claim per line, oldest first. Superseded claims stay visible. - [Abbott Laboratories](/record/abbott-laboratories.md) | operating_income | 4,578,545,000 United States dollar | valid 2007-12-31 to 2008-12-31 | conf 0.95 | superseded | superseded_by [clm_9A47D1F92763](/claim/clm_9A47D1F92763.md) | [clm_F857B97BF253](/claim/clm_F857B97BF253.md) sources: https://www.sec.gov/Archives/edgar/data/1800/000104746910001018/0001047469-10-001018-index.htm - [Abbott Laboratories](/record/abbott-laboratories.md) | operating_income | 5,693,839,000 United States dollar | valid 2008-12-31 to 2009-12-31 | conf 0.95 | superseded | superseded_by [clm_44311C0CCB22](/claim/clm_44311C0CCB22.md) | [clm_9A47D1F92763](/claim/clm_9A47D1F92763.md) sources: https://www.sec.gov/Archives/edgar/data/1800/000104746910001018/0001047469-10-001018-index.htm - [Abbott Laboratories](/record/abbott-laboratories.md) | operating_income | 6,235,741,000 United States dollar | valid 2009-12-31 to 2010-12-31 | conf 0.95 | superseded | superseded_by [clm_16CB3FB094C5](/claim/clm_16CB3FB094C5.md) | [clm_44311C0CCB22](/claim/clm_44311C0CCB22.md) sources: https://www.sec.gov/Archives/edgar/data/1800/000104746910001018/0001047469-10-001018-index.htm - [Abbott Laboratories](/record/abbott-laboratories.md) | operating_income | 6,087,581,000 United States dollar | valid 2010-12-31 to 2011-12-31 | conf 0.95 | superseded | superseded_by [clm_E857AF3C6172](/claim/clm_E857AF3C6172.md) | [clm_16CB3FB094C5](/claim/clm_16CB3FB094C5.md) sources: https://www.sec.gov/Archives/edgar/data/1800/000104746911001056/0001047469-11-001056-index.htm - [Abbott Laboratories](/record/abbott-laboratories.md) | operating_income | 5,751,948,000 United States dollar | valid 2011-12-31 to 2012-12-31 | conf 0.95 | superseded | superseded_by [clm_DB14BAE02A47](/claim/clm_DB14BAE02A47.md) | [clm_E857AF3C6172](/claim/clm_E857AF3C6172.md) sources: https://www.sec.gov/Archives/edgar/data/1800/000104746912001216/0001047469-12-001216-index.htm - [Abbott Laboratories](/record/abbott-laboratories.md) | operating_income | 8,084,515,000 United States dollar | valid 2012-12-31 to 2013-12-31 | conf 0.95 | superseded | superseded_by [clm_476B36EDFB32](/claim/clm_476B36EDFB32.md) | [clm_DB14BAE02A47](/claim/clm_DB14BAE02A47.md) sources: https://www.sec.gov/Archives/edgar/data/1800/000104746913001180/0001047469-13-001180-index.htm - [Abbott Laboratories](/record/abbott-laboratories.md) | operating_income | 2,629,000,000 United States dollar | valid 2013-12-31 to 2014-12-31 | conf 0.95 | superseded | superseded_by [clm_4095A5CF68FD](/claim/clm_4095A5CF68FD.md) | [clm_476B36EDFB32](/claim/clm_476B36EDFB32.md) sources: https://www.sec.gov/Archives/edgar/data/1800/000104746914001176/0001047469-14-001176-index.htm - [Abbott Laboratories](/record/abbott-laboratories.md) | operating_income | 2,599,000,000 United States dollar | valid 2014-12-31 to 2015-12-31 | conf 0.95 | superseded | superseded_by [clm_D45686CBE9CE](/claim/clm_D45686CBE9CE.md) | [clm_4095A5CF68FD](/claim/clm_4095A5CF68FD.md) sources: https://www.sec.gov/Archives/edgar/data/1800/000104746915001377/0001047469-15-001377-index.htm - [Abbott Laboratories](/record/abbott-laboratories.md) | operating_income | 2,867,000,000 United States dollar | valid 2015-12-31 to 2016-12-31 | conf 0.95 | superseded | superseded_by [clm_476A660B6C4B](/claim/clm_476A660B6C4B.md) | [clm_D45686CBE9CE](/claim/clm_D45686CBE9CE.md) sources: https://www.sec.gov/Archives/edgar/data/1800/000104746916010246/0001047469-16-010246-index.htm - [Abbott Laboratories](/record/abbott-laboratories.md) | operating_income | 3,185,000,000 United States dollar | valid 2016-12-31 to 2017-12-31 | conf 0.95 | superseded | superseded_by [clm_4420320133D9](/claim/clm_4420320133D9.md) | [clm_476A660B6C4B](/claim/clm_476A660B6C4B.md) sources: https://www.sec.gov/Archives/edgar/data/1800/000104746917000744/0001047469-17-000744-index.htm - [Abbott Laboratories](/record/abbott-laboratories.md) | operating_income | 1,726,000,000 United States dollar | valid 2017-12-31 to 2018-12-31 | conf 0.95 | superseded | superseded_by [clm_B2ED5C0080DE](/claim/clm_B2ED5C0080DE.md) | [clm_4420320133D9](/claim/clm_4420320133D9.md) sources: https://www.sec.gov/Archives/edgar/data/1800/000104746918000856/0001047469-18-000856-index.htm - [Abbott Laboratories](/record/abbott-laboratories.md) | operating_income | 3,650,000,000 United States dollar | valid 2018-12-31 to 2019-12-31 | conf 0.95 | superseded | superseded_by [clm_50D9545CB1D5](/claim/clm_50D9545CB1D5.md) | [clm_B2ED5C0080DE](/claim/clm_B2ED5C0080DE.md) sources: https://www.sec.gov/Archives/edgar/data/1800/000104746919000624/0001047469-19-000624-index.htm - [Abbott Laboratories](/record/abbott-laboratories.md) | operating_income | 4,532,000,000 United States dollar | valid 2019-12-31 to 2020-12-31 | conf 0.95 | superseded | superseded_by [clm_3EFF550A655C](/claim/clm_3EFF550A655C.md) | [clm_50D9545CB1D5](/claim/clm_50D9545CB1D5.md) sources: https://www.sec.gov/Archives/edgar/data/1800/000110465920023904/0001104659-20-023904-index.htm - [Abbott Laboratories](/record/abbott-laboratories.md) | operating_income | 5,357,000,000 United States dollar | valid 2020-12-31 to 2021-12-31 | conf 0.95 | superseded | superseded_by [clm_92EA1FC35D1F](/claim/clm_92EA1FC35D1F.md) | [clm_3EFF550A655C](/claim/clm_3EFF550A655C.md) sources: https://www.sec.gov/Archives/edgar/data/1800/000110465921025751/0001104659-21-025751-index.htm - [Abbott Laboratories](/record/abbott-laboratories.md) | operating_income | 8,425,000,000 United States dollar | valid 2021-12-31 to 2022-12-31 | conf 0.95 | superseded | superseded_by [clm_504246A9C0D6](/claim/clm_504246A9C0D6.md) | [clm_92EA1FC35D1F](/claim/clm_92EA1FC35D1F.md) sources: https://www.sec.gov/Archives/edgar/data/1800/000110465922025141/0001104659-22-025141-index.htm - [Abbott Laboratories](/record/abbott-laboratories.md) | operating_income | 8,362,000,000 United States dollar | valid 2022-12-31 to 2023-12-31 | conf 0.95 | superseded | superseded_by [clm_492DDC48ED34](/claim/clm_492DDC48ED34.md) | [clm_504246A9C0D6](/claim/clm_504246A9C0D6.md) sources: https://www.sec.gov/Archives/edgar/data/1800/000162828023004026/0001628280-23-004026-index.htm - [Abbott Laboratories](/record/abbott-laboratories.md) | operating_income | 6,478,000,000 United States dollar | valid 2023-12-31 to 2024-12-31 | conf 0.95 | superseded | superseded_by [clm_6578DDE458E0](/claim/clm_6578DDE458E0.md) | [clm_492DDC48ED34](/claim/clm_492DDC48ED34.md) sources: https://www.sec.gov/Archives/edgar/data/1800/000162828024005348/0001628280-24-005348-index.htm - [Abbott Laboratories](/record/abbott-laboratories.md) | operating_income | 6,825,000,000 United States dollar | valid 2024-12-31 to 2025-12-31 | conf 0.95 | superseded | superseded_by [clm_551396362E4C](/claim/clm_551396362E4C.md) | [clm_6578DDE458E0](/claim/clm_6578DDE458E0.md) sources: https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm - [Abbott Laboratories](/record/abbott-laboratories.md) | operating_income | 8,053,000,000 United States dollar | valid 2025-12-31 to present | conf 0.95 | valid | [clm_551396362E4C](/claim/clm_551396362E4C.md) sources: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm ## What replaced what - $4.58 billion (2007-12-31 to 2008-12-31, [clm_F857B97BF253](/claim/clm_F857B97BF253.md)) was replaced by $5.69 billion from 2008-12-31 ([clm_9A47D1F92763](/claim/clm_9A47D1F92763.md)) - $5.69 billion (2008-12-31 to 2009-12-31, [clm_9A47D1F92763](/claim/clm_9A47D1F92763.md)) was replaced by $6.24 billion from 2009-12-31 ([clm_44311C0CCB22](/claim/clm_44311C0CCB22.md)) - $6.24 billion (2009-12-31 to 2010-12-31, [clm_44311C0CCB22](/claim/clm_44311C0CCB22.md)) was replaced by $6.09 billion from 2010-12-31 ([clm_16CB3FB094C5](/claim/clm_16CB3FB094C5.md)) - $6.09 billion (2010-12-31 to 2011-12-31, [clm_16CB3FB094C5](/claim/clm_16CB3FB094C5.md)) was replaced by $5.75 billion from 2011-12-31 ([clm_E857AF3C6172](/claim/clm_E857AF3C6172.md)) - $5.75 billion (2011-12-31 to 2012-12-31, [clm_E857AF3C6172](/claim/clm_E857AF3C6172.md)) was replaced by $8.08 billion from 2012-12-31 ([clm_DB14BAE02A47](/claim/clm_DB14BAE02A47.md)) - $8.08 billion (2012-12-31 to 2013-12-31, [clm_DB14BAE02A47](/claim/clm_DB14BAE02A47.md)) was replaced by $2.63 billion from 2013-12-31 ([clm_476B36EDFB32](/claim/clm_476B36EDFB32.md)) - $2.63 billion (2013-12-31 to 2014-12-31, [clm_476B36EDFB32](/claim/clm_476B36EDFB32.md)) was replaced by $2.6 billion from 2014-12-31 ([clm_4095A5CF68FD](/claim/clm_4095A5CF68FD.md)) - $2.6 billion (2014-12-31 to 2015-12-31, [clm_4095A5CF68FD](/claim/clm_4095A5CF68FD.md)) was replaced by $2.87 billion from 2015-12-31 ([clm_D45686CBE9CE](/claim/clm_D45686CBE9CE.md)) - $2.87 billion (2015-12-31 to 2016-12-31, [clm_D45686CBE9CE](/claim/clm_D45686CBE9CE.md)) was replaced by $3.19 billion from 2016-12-31 ([clm_476A660B6C4B](/claim/clm_476A660B6C4B.md)) - $3.19 billion (2016-12-31 to 2017-12-31, [clm_476A660B6C4B](/claim/clm_476A660B6C4B.md)) was replaced by $1.73 billion from 2017-12-31 ([clm_4420320133D9](/claim/clm_4420320133D9.md)) - $1.73 billion (2017-12-31 to 2018-12-31, [clm_4420320133D9](/claim/clm_4420320133D9.md)) was replaced by $3.65 billion from 2018-12-31 ([clm_B2ED5C0080DE](/claim/clm_B2ED5C0080DE.md)) - $3.65 billion (2018-12-31 to 2019-12-31, [clm_B2ED5C0080DE](/claim/clm_B2ED5C0080DE.md)) was replaced by $4.53 billion from 2019-12-31 ([clm_50D9545CB1D5](/claim/clm_50D9545CB1D5.md)) - $4.53 billion (2019-12-31 to 2020-12-31, [clm_50D9545CB1D5](/claim/clm_50D9545CB1D5.md)) was replaced by $5.36 billion from 2020-12-31 ([clm_3EFF550A655C](/claim/clm_3EFF550A655C.md)) - $5.36 billion (2020-12-31 to 2021-12-31, [clm_3EFF550A655C](/claim/clm_3EFF550A655C.md)) was replaced by $8.43 billion from 2021-12-31 ([clm_92EA1FC35D1F](/claim/clm_92EA1FC35D1F.md)) - $8.43 billion (2021-12-31 to 2022-12-31, [clm_92EA1FC35D1F](/claim/clm_92EA1FC35D1F.md)) was replaced by $8.36 billion from 2022-12-31 ([clm_504246A9C0D6](/claim/clm_504246A9C0D6.md)) - $8.36 billion (2022-12-31 to 2023-12-31, [clm_504246A9C0D6](/claim/clm_504246A9C0D6.md)) was replaced by $6.48 billion from 2023-12-31 ([clm_492DDC48ED34](/claim/clm_492DDC48ED34.md)) - $6.48 billion (2023-12-31 to 2024-12-31, [clm_492DDC48ED34](/claim/clm_492DDC48ED34.md)) was replaced by $6.83 billion from 2024-12-31 ([clm_6578DDE458E0](/claim/clm_6578DDE458E0.md)) - $6.83 billion (2024-12-31 to 2025-12-31, [clm_6578DDE458E0](/claim/clm_6578DDE458E0.md)) was replaced by $8.05 billion from 2025-12-31 ([clm_551396362E4C](/claim/clm_551396362E4C.md)) ## Questions this record answers ### What is Abbott Laboratories's current operating income? The latest figure on the record is $1.36 billion for the quarter ended September 30, 2026, from a primary source (sec.gov). The latest full-year figure is $8.05 billion, dated December 31, 2025, from a primary source (sec.gov). The record asserts both as of November 9, 2026. ### What was Abbott Laboratories's operating income for the quarter ended September 30, 2026? $1.36 billion for the quarter ended September 30, 2026, dated September 30, 2026, from a primary source (sec.gov) (status valid, confidence 0.95). ### When did Abbott Laboratories's operating income last change? The latest value on the record is $8.05 billion, dated December 31, 2025; before it the record holds $6.83 billion, dated December 31, 2024 and closed on December 31, 2025. ### What was Abbott Laboratories's operating income before $8.05 billion? $6.83 billion, valid from December 31, 2024 to December 31, 2025 (status superseded), from a primary source (sec.gov). ## Read on - This page: /record/abbott-laboratories/operating_income (markdown: /record/abbott-laboratories/operating_income.md) - Entity twin: /record/abbott-laboratories.md ยท timeline: /timelines/abbott-laboratories.md --- AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.